PTGX(Protagonist Therapeutics, Inc.) · 财务报表

PTGX(Protagonist Therapeutics, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$27.36M$26.58M$60.00M$434.43M$46.02M
毛利润—————
营业利润−$125.84M−$131.37M−$93.65M$252.84M−$158.13M
净利润−$125.55M−$127.39M−$78.95M$275.19M−$130.15M
经营现金流−$107.86M−$108.14M−$70.24M$184.15M$57.67M
自由现金流−$108.97M−$108.93M−$70.84M$182.80M$56.08M
摊薄每股收益$-2.71$-2.60$-1.39$4.23$-2.05

Protagonist Therapeutics, Inc. PTGX